The recent failure of bevacizumab in the adjuvant setting has forced us to consider what has gone wrong. It is possible that with careful analysis and novel biomarkers, we may not yet have to lay bevacizumab to rest.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335–2342 (2004).
Allegra, C. J. et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J. Clin. Oncol. 29, 11–16 (2011).
De Gramont, A. et al. AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer [abstract]. J. Clin. Oncol. 29 (Suppl. 4), a362 (2011).
Mancuso, M. R. et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 116, 2610–2621 (2006).
Cacheux, W. et al. Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. Ann. Oncol. 19, 1659–1661 (2008).
Jubb, A. M. & Harris, A. L. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol. 11, 1172–1183 (2010).
Xu, L. et al. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res. 69, 7905–7910 (2009).
Saltz, L. B. et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol. 26, 2013–2019 (2008).
Jain, R. K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7, 987–989 (2001).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D. J. Kerr receives honoraria and research support from Roche. A. M. Young declares no competing interests.
Rights and permissions
About this article
Cite this article
Kerr, D., Young, A. Bevacizumab—has it reached its final resting place?. Nat Rev Clin Oncol 8, 195–196 (2011). https://doi.org/10.1038/nrclinonc.2011.32
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.32
This article is cited by
-
Use of Bevacizumab in the Management of Potentially Resectable Colorectal Liver Metastases: Safety, Pathologic Assessment and Benefit
Current Colorectal Cancer Reports (2016)
-
Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?
Cellular and Molecular Life Sciences (2013)
-
First-line bevacizumab for ovarian cancer—new standard of care?
Nature Reviews Clinical Oncology (2012)
-
Tumorangiogenese und aktuelle therapeutische Möglichkeiten der Inhibition
Der Onkologe (2011)